Week Five Sponsor Adequan� Presents "There is NO GENERIC ADEQUAN i.m." Campaign at the 2013 FTI WEF
For Immediate Release Lauren Fisher for Jennifer Wood Media, Inc.
Wellington, FL - February 6, 2013 - Equestrian Sport Productions welcomes Adequan� as the week five title sponsor of the 2013 FTI Consulting Winter Equestrian Festival (FTI WEF). Running February 6 - 10, week five will feature the $82,000 Adequan Grand Prix, CSI 2* on Saturday, February 9. In addition to their generous weekly sponsorship, Adequan is the overall circuit sponsor of the Young Jumper divisions for Five Year Olds, Six Year Olds, and Seven/Eight Year Olds. The 12-week FTI WEF runs through March 31, 2013, awarding almost $7 million in prize money throughout the circuit.
Allyn G. Mann, Director of the Animal Health Division at Luitpold Pharmaceuticals, Inc., is proud to return with Adequan for the company's fourth year as a weekly sponsor at the FTI WEF. Mann explained the establishment of Adequan's sponsorship, stating, "Adequan has participated in the past in smaller roles, but when the opportunity presented itself to become one of the 12 weekly sponsors it made sense, especially since many users of our product, Adequan, are competing here every week."
"We are also very excited about our new opportunity with Equestrian Sport Productions as title sponsor of the Adequan Global Dressage Festival," Mann said. "This makes complete sense as the dressage horse and the people who own them are committed for the long haul. This group recognizes there are no shortcuts to success and are committed to providing the best care possible for their animals."
The "NO GENERIC ADEQUAN i.m." campaign
There is a lot of false and misleading information out there about joint treatments. But when it comes to the performance, safety and health of your horse, you can't afford to choose your joint treatment regimen on anything less than the hard facts. Here are some key facts that you need to know.
What is a generic drug?
According to the FDA, a generic drug is bioequivalent to the innovator drug and is also FDA approved. The approval process is easier and faster for a generic drug than an innovator drug because the manufacturer doesn't have to conduct preclinical or clinical studies. However, the manufacturer must scientifically prove the generic drug performs in the same manner as the innovator drug.
After a generic drug is approved, the manufacturer also must comply with the same regulations as the pioneer drug. The marketing and labeling must be reviewed and approved so it doesn't mislead the public. Even generic products will have a product insert in every box.
Not every innovator drug has a generic brand available to the market. For example, Adequan i.m. (Polysulfated Glycosaminogycan) has no generic equivalent. Because generic drugs are FDA approved, it is illegal to call a product the generic form of another drug when it has not been FDA approved as such.
When prescribing a product to treat or prevent a disease, it is important to know what the product is proven to do. Is it a drug that is proven to create a desired reaction, or is it a device that should be used as a final wash? Is it a generic version of a successful product that is FDA approved, or is it a compounded product for a unique situation? The client depends on the veterinarian to make the ethical choice and inform them of the best treatment options for their animal.
Learn More About Adequan
Adequan� is a registered trademark of Luitpold Pharmaceuticals, Inc. Luitpold Animal Health, based in Shirley, N.Y., markets Adequan� i.m. and Adequan� i.a. for horses and Adequan� Canine for dogs. The company is committed to advancing the cause of better health for equine and canine breeds.
Adequan has also added an educational component to their sponsorship this year. During Adequan week, Dr. Victoria Maxwell will be presenting a Lunch & Learn on Thursday, February 7, at 11:30 am in The Wellington Club on choosing the right treatment for joint problems. Dr. Maxwell plans to share information that will focus on how best to maintain healthy functioning joints as well as understanding the choices available to treat your horse's joint problems.
Mann explained, "Dr. Maxwell does an excellent job of making this scientific topic easy to understand. We also have excellent educational tools that are made available throughout the entire show. It is important that everyone receives quality information that is based on science, not opinion. Our goal is to provide scientific messages that are simple to comprehend and useful for all equine enthusiasts."
Mann is happy to continue Adequan's involvement with the horse show and excited for a fantastic week of competition.
"It is very impressive to see the vast improvements that have been made (and continue to be made) to create a world-class facility. From a sponsor's standpoint, this is the place to be for 12 weeks of the year," he stated. "The staff I spend time with, especially Meg Krueger, understand sponsorships are more than just putting up some banners, an ad in the program, and a few PA announcements. Their vision is endless when it comes to creating added value for sponsors and the channel of communication is very effective. We are excited to be a part of the Palm Beach International Equestrian Center and look forward to a long-term relationship."
Luitpold Pharmaceuticals, Inc. Animal Health Division is committed to advancing the cause of equine health. Due to the rigors of competition, many performance horses suffer from joint disease. Adequan� is designed to help treat the underlying cause of the problem and break the cycle of damage, while reducing pain and inflammation. For more information about products from Luitpold Animal Health visit www.adequan.com.
You can also learn the facts about our NO GENERIC ADEQUAN i.m. campaign by visiting www.nogenericadequan.com.
Please visit www.equestriansport.com or call 561-793-5867 for more information on the 2013 FTI Consulting Winter Equestrian Festival.
  
|
